Zyprexa

Ranbaxy is India's biggest drugmaker, with $1.16 billion in 2004 sales.

Today's ruling is the second time a U.S.

court has rebuffed efforts by a generic-drug company challenging a patent on the main compound for a drug.

In April, a judge in Indiana upheld the compound patent for Eli Lilly & Co.'s The case is Pfizer Inc.

v.

Ranbaxy Laboratories Ltd., 03cv209, U.S.

District Court, District of Delaware (Wilmington).

To contact the reporters on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net; Nicole Ostrow in New York at nostrow@bloomberg.net.

Last Updated: December 16, 2005 17:29 EST ©2005 Bloomberg L.P.

All rights reserved.

Terms of Service Privacy Policy Trademarks Site Map Help Feedback About Bloomberg Log In/Register Advertising 日本語サイト ...

Read more...